A Phase 1 interventional study of GRT6019 in Duchenne Muscular Dystrophy (DMD), sponsored by Grünenthal GmbH. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 107th largest by enrollment of the 171 interventional ones that give a count, is one of 10 that started in 2025, is one of 32 in phase 1, and was the 225th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Grünenthal GmbH has 3 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the safety, tolerability, and Pharmacokinetics (PK) of a single oral dose of GRT6019 in healthy male participants, including food effect.
This is an open-label, single-dose, single-center Phase I trial with healthy male participants. The trial will consist of 2 cohorts with a total duration of approximately 7 weeks, including a 28-day Screening Period.
The participants will receive a single dose of GRT6019 administered on Day 1 and will remain at the clinic for 7 additional days.
Following the in-house stay, there will be 2 Follow-up Visits up until Day 23, with 3 clinic visits scheduled
Cohort 1 and Cohort 2 will be dosed in parallel:
Main inclusion Criteria:
Main exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fed State
Drug: GRT6019
Fasted State
Drug: GRT6019
Single Dose
Also known as: Study drug
Number of participants with Adverse Events
Assessment of safety and tolerability of GRT6019 after a single oral dose
Time frame: Through study completion, an average of 7 Weeks
Number of participants with serious Adverse Events
Assessment of safety and tolerability of GRT6019 after a single oral dose
Time frame: Through study completion, an average of 7 Weeks
Number of participants with Adverse Events leading to discontinuation
Assessment of safety and tolerability of GRT6019 after a single oral dose
Time frame: Through study completion, an average of 7 Weeks
Number of participants with Adverse Events related with GRT6019
Assessment of safety and tolerability of GRT6019 after a single oral dose
Time frame: Through study completion, an average of 7 Weeks
Area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUC0-t)
The total amount of the study drug in the blood from the time it is taken until the last time a measurable level of the drug is found. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time (AUC0-inf )
The total amount of the study drug in the blood from the time it is taken until it has completely left the body. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Maximum plasma concentration (Cmax)
The maximum amount of the study drug measured in the blood after taking the dose. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Time of maximum plasma concentration (Tmax)
The time it takes to reach the highest concentration of the study drug in the blood after dosing. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Lag-time observed from dosing to the time point prior to that of the first quantifiable plasma concentration (Tlag). Assessment of the PK of GRT6019 following a single oral dose of the pediatric formulation under fasted and fed conditions.
The time between when the study drug is taken and when it first becomes measurable in the blood. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Terminal elimination half life (T₁/₂)
The time it takes for the amount of study drug in the blood to reduce by half after reaching its peak level. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Total body oral clearance (CL/F)
The amount of blood completely cleared of thestudy drug (and metabolite) per unit of time, taking into account how much of the drug is absorbed into the body. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Apparent volume of distribution (V/F)
An estimate of how widely the study drug spreads through the body's tissues after it is absorbed. Assessment of the PK of GRT6019 following a single dose under fasted and fed conditions.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Ratio of the geometric mean of AUC0-t
Assessment of the effect of food (fed and fasted state) on the PK of GRT6019 following a single dose.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Ratio of the geometric mean of AUC0-inf
Assessment of the effect of food (fed and fasted state) on the PK of GRT6019 following a single dose.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Ratio of the geometric mean of Cmax
Assessment of the effect of food (fed and fasted state) on the PK of GRT6019 following a single dose.
Time frame: From pre-dose (at -2 hours to -5 minutes ) to 528 hours post-dose.
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in Jan 2026, 1 month.
Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegacorat
Muscular Dystrophy, Duchenne →